Home

TRV GP II, LLC

CIK 1614073 · last filed 2020-11-13

TRV GP II, LLC is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for JNCE, was dated Nov 13, 2020. The firm reports its address in Boston, MA. 50 SEC filings were submitted jointly with MARK J LEVIN.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
THIRD ROCK VENTURES
29 NEWBURY STREET, 3RD FLOOR
BOSTON, MA 02116
Phone
(617) 585-2000
State of Incorporation
DE
Related Filers
MARK J LEVIN — 50 joint filings, latest 2021-09-17
Third Rock Ventures GP II, L.P. — 50 joint filings, latest 2021-09-17
Third Rock Ventures II, L.P. — 50 joint filings, latest 2021-09-17
ROBERT I TEPPER — 46 joint filings, latest 2021-09-17
KEVIN P STARR — 29 joint filings, latest 2021-09-17
TRV GP III, LLC — 9 joint filings, latest 2020-02-18
Third Rock Ventures GP III, L.P. — 9 joint filings, latest 2020-02-18
Third Rock Ventures III, L.P. — 9 joint filings, latest 2020-02-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Jounce Therapeutics, Inc. (JNCE) Delisted 10%+ Owner 53,592 $1.88 $100.8K $0 1 2020-11-13
Sage Therapeutics, Inc. (SAGE) Delisted 10%+ Owner 49,241 $8.68 $427.4K $0 2 2015-08-18

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-11-13 Jounce Therapeutics, Inc. (JNCE) Delisted Other (J) −6,000,000 $0 EDGAR
2015-08-18 Sage Therapeutics, Inc. (SAGE) Delisted Other (J) −11,431,685 $0 EDGAR
2015-01-20 Sage Therapeutics, Inc. (SAGE) Delisted Other (J) −3,263,790 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.